GSK said on that its blood cancer drug Blenrep had reached a key goal in a late-stage trial, as the British drugmaker looks to bolster its oncology business after a series of setbacks.
Last November Blenrep failed to meet the main goal in a late-stage study that was designed to show it was better than an existing treatment on the market, leading GSK to stop selling the drug in the United States.
The company had said this month that Blenrep failed the main goal of a key study designed to show it was better than an existing treatment on the market, stoking fears that regulatory approval could be rescinded by the FDA.
GSK’s oncology business suffers fresh blow with Zejula setback By Natalie Grover and Pushkala Aripaka Nov 11 (Reuters) – Britain’s GSK (GSK.L) said on Friday it would limit the use […]
The company announced that its blood cancer drug Blenrep failed the main goal of a late-stage study designed to show it was better than an existing treatment on the market.
When GlaxoSmithKline’s consumer health spinoff Haleon launches later this month, the new business will carry more than $12 billion in debt when it lists on the London Stock Exchange.